More Stories

Informist, Monday, Apr. 27, 2026

MUMBAI – Sun Pharmaceutical Industries Ltd. Monday said it entered into a definitive agreement to acquire US-based healthcare company, Organon & Co. for $14 per share in an all cash transaction with an enterprise valuation of $11.75 billion. The acquisition, expected to be completed by early 2026, will be funded through a combination of available cash resources and banks loans, Sun Pharma said in an exchange filing. Organon will be merged with a subsidiary of Sun Pharma, it said, without disclosing the name of the arm.   

"This transaction is a logical next step in strengthening Sun Pharma's global business. Together, we will become a partner of choice for acquiring and launching new products," Kirti Ganorkar, managing director of Sun Pharma, said in the filing. "We see strong potential in leveraging Organon's talent pool. In addition, there is a scope for synergies, including significant revenue upside opportunities to be realised over the coming years." The immediate priorities will be business continuity, disciplined integration and value creation, Ganorkar said.

The transaction has been approved by boards of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders, Sun Pharma said. The proposed acquisition is aligned with Sun Pharma's strategy of growing its innovative medicines business, the company said. The deal also enables its entry into biosimilars as a top-10 global player.  

For the year ended Dec. 31, Organon reported revenue of $6.2 billion and adjusted earnings before interest, taxes, depreciation, and amortisation of $1.9 billion, Sun Pharma said. Organon had a debt of $8.6 billion and cash balance of $574 million. Further, it has recently closed divestment of a product for which it received an upfront payment of $440 million, the net proceeds of which will further contribute to its cash balance.  
   

For the December quarter, Sun Pharma reported a consolidated net profit of INR 33.69 billion on revenues of INR 155.21 billion. At 0930 IST, shares of the company closed 3.6% higher at INR 1,680 on the National Stock Exchange.  End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Reported by Arya S. Biju

Edited by Tanima Banerjee

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000  

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.